Phospholipase A2 group IVC (PLA2G4C)

Phospholipase A2 group IVC (PLA2G4C), also known as cytosolic phospholipase A2 gamma (cPLA2-gamma), is a calcium-independent, membrane-bound enzyme of the cytosolic phospholipase A2 family[1][3]. It hydrolyzes glycerophospholipids to generate free fatty acids (notably arachidonic acid) and lysophospholipids, serving as a pivotal player in lipid mediator signaling and membrane lipid remodeling[3]. PLA2G4C displays robust lysophospholipase and transacylase activities and localizes to cellular sites such as the endoplasmic reticulum, mitochondria, and peroxisomes, thus contributing to lipid and energy metabolism[3]. The enzyme has important roles in the regulation of prostaglandin synthesis in tissues such as the uterine endometrium and modulates cell migration, chemotactic signaling, and macrophage immune functions. Genetic variations in this gene are linked to risks and prognosis in diseases including colorectal cancer and neuropsychiatric disorders[3]. It is considered a potential therapeutic target in inflammation and cancer, but no approved drugs currently target this protein directly[2][3].

Other names

Cytosolic phospholipase A2 gammacPLA2-gammacPLA2γCytosolic lysophospholipaseCytosolic lysophospholipid O-acyltransferasePhospholipase A2, group IVC (cytosolic, calcium-independent)D7Ertd445ePla2g4cl1Pla2g4cl2

Competitive or allosteric inhibition of phospholipase A2 activity (for PLA2 family inhibitors; no specific PLA2G4C inhibitors approved)[2].